FluoGuide invites to presentation of FG001 results from the first clinical trial in aggressive brain cancer on 17 May 2022

Copenhagen, Denmark, 6 May 2022 – FluoGuide A/S (“FluoGuide” or the “Company”) invites to a presentation of the results from the clinical trial of FG001 used to guide surgery in patients with aggressive high-grade glioma brain cancer, which will first be presented at the 68th Scandinavian Neurosurgical Society (SNS) Congress held 14-16 May 2022, in Bergen, Norway

The release as fetched from its publisher. fluoguide.com ↗